Adaptimmune Therapeutics Earning Date (ADAP)

USA |NASDAQ |USD

ADAP Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Feb 23, 2022 Dec 2021 $-0.06 $-0.30 $-0.24
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Feb 23, 2022 Dec 2021 $77.76M $1.20M $1.50M

Adaptimmune Therapeutics's next earnings date is Wednesday, Feb 23, 2022 for the fiscal quarter ending Dec 2021.

ADAP Earnings Date & History Chart

ADAP Earnings & Revenue Forecast

ADAP Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Mar 2022 3 $-0.26 $-0.29 $-0.22
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 6 $-0.99 $-1.15 $-0.80

ADAP Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Mar 2022 0 / 0 $-0.26 $-0.27 $-0.27
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-0.99 $-1.00 $-1.00

ADAP Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Mar 2022 3 $3.33M $500.00K $7.50M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 8 $15.39M $0.00 $42.20M

ADAP Earnings Date & Revenue History

ADAP Earnings History

|
Show More
Show More

ADAP Revenue History

|
Show More
Show More

Adaptimmune Therapeutics Next Earnings Date & Report

ADAP Next Earnings Date & Report Preview: Dec 2021 (FQ)

ADAP's next earnings date is Wednesday, Feb 23, 2022 for the fiscal quarter ending Dec 31, 2021.

According to 5 analysts, the average EPS estimation for Adaptimmune Therapeutics's next quarterly earnings is $-0.06, with a low EPS estimation of $-0.27, and a high estimation of $0.71.

Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.06, the last 2 month trend is $-0.26, and the 3 month trend is $-0.26.

Based on 7 analysts, the average revenue estimation is $77.76M, with a low revenue estimation of $400.00K, and a high estimation of $159.00M.

Adaptimmune Therapeutics Previous Earnings Dates & Reports

ADAP Previous Earnings Date & Report Recap: Sep 2021 (FQ)

Adaptimmune Therapeutics's previous earnings date was Nov 4, 2021 for its fiscal quarter ended Sep 30, 2021.

ADAP's earnings per share (EPS) was $-0.30, missing the consensus analysts forecast of $-0.27 by -13.21%.

The EPS was lower than the previous fiscal quarter (Jun 2021) by 25.00%, and lower than the same period a year before (Sep 2020) by 25.00%.

Revenues were $1.20M, worse than the forecast of $1.37M by -12.19%, down by -61.13% from the previous quarter , and up by 0.84% from the same period last year.

The company reported a net income of $-42.40M.

Free cash flow for the quarter was $-46.87M , compared to $-33.24M last quarter and $-17.12M a year before.

ADAP ended the quarter with $25.97M in total debt, an increase of 14.69% compared to the previous quarter, and an increase of 9.54% compared to the same quarter a year before.

ADAP Previous Earnings Date & Report Recap: Dec 2020 (FY)

Adaptimmune Therapeutics's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.

ADAP's earnings per share (EPS) was $-0.96, missing the consensus analysts forecast of $-0.90 by 6.67% , and higher than the previous year's EPS (Dec 2019) by -27.27%.

Revenues were $3.96M, better than the forecast of $3.29M by 20.30%, and up by 252.76% from previous year's revenue.

The company reported a net income of $-130.09M.

Adaptimmune Therapeutics reported a free cash flow of $-56.50M for its fiscal year, compared to $-115.58M a year ago.

The company ended the fiscal year with $23.71M in total debt, a decrease of -6.87% compared to the previous year.